Physician

Alexander I Zuhoski, MD

According to 2025 Medicare claims, Alexander Zuhoski, MD (NPI: 1992740856) practices medical oncology in the Nassau County-Suffolk County, NY market, with the plurality of this provider's patient population coming from Suffolk, NY. This provider's primary affiliated billing organization is NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (NPI: 1396794574; TIN: 112419534) and primary practice location at 11901-9999. Zuhoski is affiliated with the ilumed, LLC (ACO ID: D0005) and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Zuhoski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,794 traditional Medicare patients, billed 309,881 HCPCS/CPT codes, and received $4,560,305 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,088 prescription claims across 320 beneficiaries totaling $12,679,698 in drug costs, led by Octagam (Immun Globg(Igg)/Malt/Iga Ov50). DME data shows 24 claims. Open Payments data shows 1 records totaling $20. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,709,343 to $12,679,698. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,511	456,296	$3,778,934
2016	1,460	512,892	$5,039,243
2017	1,481	570,276	$5,745,440
2018	1,653	565,597	$6,610,660
2019	1,951	689,608	$8,018,073
2020	2,078	710,906	$8,819,819
2021	2,082	654,174	$8,693,747
2022	1,931	557,585	$7,934,314
2023	2,159	467,203	$6,347,242
2024	1,794	309,881	$4,560,305

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	244	1,254	$1,709,343
2016	249	1,269	$1,388,798
2017	219	1,247	$1,442,266
2018	236	1,560	$2,807,685
2019	309	1,914	$3,871,612
2020	280	2,097	$5,961,559
2021	295	2,026	$6,687,778
2022	302	2,286	$7,857,678
2023	315	2,735	$10,880,183
2024	320	3,088	$12,679,698

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	80	$56,134
2016	N/R	119	$70,464
2017	N/R	40	$9,062
2018	22	44	$6,502
2019	N/R	33	$3,749
2020	N/R	36	$2,088
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	50	$3,602
2024	N/R	24	$1,080

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	933	2,574	$108
80053	Blood test, comprehensive group of blood chemicals	1,333	3,856	$10
36415	Insertion of needle into vein for collection of blood sample	1,510	4,818	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,418	4,761	$8
83615	Lactate dehydrogenase (enzyme) level	877	1,973	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	162	4,593	$1,525,363
Aranesp	Darbepoetin Alfa In Polysorbat	354	7,476	$1,325,959
Imbruvica	Ibrutinib	56	1,636	$900,726
Revlimid	Lenalidomide	46	1,260	$801,960
Xtandi	Enzalutamide	51	1,530	$725,326

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	11	$812
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$268

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$20	CSL Behring
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alexander I. Zuhoski, MD?

Tedicare shows public-source Medicare data for Alexander I. Zuhoski, MD (NPI 1992740856), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alexander I. Zuhoski, MD have ACO affiliation data?

Alexander I. Zuhoski, MD is shown with ACO affiliation data for ilumed, LLC (REACH, ACO ID D0005) and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Alexander I. Zuhoski, MD?

Alexander I. Zuhoski, MD is linked to NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (billing NPI 1396794574) in the available physician profile data.

Does Alexander I. Zuhoski, MD have Open Payments data?

Alexander I. Zuhoski, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.